AUPH Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
83.2M
+7.1%
77.7M
+0.8%
77.1M
+5.0%
73.5M
+4.9%
70.0M
Cost of Revenue
6.6M
+0.8%
6.5M
-26.1%
8.8M
+7.6%
8.2M
+14.9%
7.1M
Gross Profit
76.7M
+7.7%
71.2M
+4.2%
68.3M
+4.6%
65.3M
+3.8%
62.9M
Operating Expenses
30.3M
+1.8%
29.8M
-40.1%
49.7M
+43.5%
34.6M
-19.1%
42.8M
R&D
13.1M
+74.7%
7.5M
-31.4%
10.9M
+29.2%
8.4M
+13.5%
7.4M
SG&A
23.5M
+6.7%
22.0M
-24.7%
29.3M
+11.7%
26.2M
+0.6%
26.0M
Operating Income
46.3M
+11.9%
41.4M
+122.3%
18.6M
-39.2%
30.7M
+52.7%
20.1M
EBITDA
51.2M
+10.7%
46.2M
+96.8%
23.5M
-33.9%
35.5M
+41.8%
25.1M
Net Income
37.4M
+8.9%
34.4M
-83.7%
210.8M
+568.1%
31.6M
+46.7%
21.5M
EPS (Basic)
$0.29
+11.5%
$0.26
-83.8%
$1.60
+566.7%
$0.24
+50.0%
$0.16
EPS (Diluted)
$0.28
+12.0%
$0.25
-83.7%
$1.53
+565.2%
$0.23
+43.8%
$0.16
Shares (Diluted)
133.5M
-3.0%
137.6M
-0.3%
138.1M
+1.5%
136.0M
-1.1%
137.5M
Aurinia Pharmaceuticals (AUPH) โ€” Financials